Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $197.95 | 7 | 71.2% |
| Education | $79.99 | 1 | 28.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $127.03 | 2 | $0 (2023) |
| Astellas Pharma US Inc | $79.99 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $37.95 | 3 | $0 (2021) |
| GlaxoSmithKline, LLC. | $21.02 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $11.95 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $114.26 | 1 | Merck Sharp & Dohme LLC ($114.26) |
| 2021 | $117.94 | 4 | Astellas Pharma US Inc ($79.99) |
| 2020 | $45.74 | 3 | GlaxoSmithKline, LLC. ($21.02) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/22/2023 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $114.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/12/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 07/07/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/15/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/27/2020 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.95 | General |
| Category: Cardiovascular | ||||||
| 05/27/2020 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: ONCOLOGY | ||||||
| 03/02/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 196 | 592 | $88,310 | $46,951 |
| 2022 | 4 | 208 | 756 | $106,905 | $53,617 |
| 2021 | 4 | 277 | 921 | $121,155 | $63,977 |
| 2020 | 4 | 335 | 948 | $133,350 | $70,536 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 111 | 493 | $61,625 | $34,693 | 56.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 68 | 75 | $25,125 | $11,238 | 44.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 17 | 24 | $1,560 | $1,020 | 65.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 104 | 619 | $77,375 | $38,533 | 49.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 65 | 73 | $24,455 | $12,302 | 50.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 26 | $2,605 | $1,647 | 63.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 26 | 38 | $2,470 | $1,134 | 45.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 144 | 713 | $89,125 | $45,208 | 50.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 55 | 58 | $19,430 | $10,218 | 52.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 42 | 95 | $9,025 | $6,693 | 74.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 36 | 55 | $3,575 | $1,857 | 51.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 179 | 714 | $89,250 | $46,542 | 52.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 89 | 95 | $31,825 | $17,149 | 53.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 42 | 108 | $10,260 | $5,787 | 56.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 25 | 31 | $2,015 | $1,059 | 52.5% |
About Dr. Mark Finch, M.D
Dr. Mark Finch, M.D is a Infectious Disease healthcare provider based in Hayward, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730248196.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Finch, M.D has received a total of $277.94 in payments from pharmaceutical and medical device companies, with $114.26 received in 2023. These payments were reported across 8 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($197.95).
As a Medicare-enrolled provider, Finch has provided services to 1,016 Medicare beneficiaries, totaling 3,217 services with total Medicare billing of $235,081. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Hayward, CA
- Active Since 12/08/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1730248196
Products in Payments
- RECARBRIO (Drug) $114.26
- BRILINTA (Drug) $37.95
- ZEJULA (Drug) $21.02
- ZERBAXA (Drug) $12.77
- ELIQUIS (Drug) $11.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.